These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 25097079)
1. Vaccination against zoster remains effective in older adults who later undergo chemotherapy. Tseng HF; Tartof S; Harpaz R; Luo Y; Sy LS; Hetcher RC; Jacobsen SJ Clin Infect Dis; 2014 Oct; 59(7):913-9. PubMed ID: 25097079 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Tseng HF; Smith N; Sy LS; Jacobsen SJ Vaccine; 2011 May; 29(20):3628-32. PubMed ID: 21435407 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Herpes Zoster Vaccine in Patients 60 Years and Older With End-stage Renal Disease. Tseng HF; Luo Y; Shi J; Sy LS; Tartof SY; Sim JJ; Hechter RC; Jacobsen SJ Clin Infect Dis; 2016 Feb; 62(4):462-7. PubMed ID: 26671505 [TBL] [Abstract][Full Text] [Related]
4. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population. Tseng HF; Chi M; Smith N; Marcy SM; Sy LS; Jacobsen SJ J Infect Dis; 2012 Jul; 206(2):190-6. PubMed ID: 22669900 [TBL] [Abstract][Full Text] [Related]
5. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. Tseng HF; Smith N; Harpaz R; Bialek SR; Sy LS; Jacobsen SJ JAMA; 2011 Jan; 305(2):160-6. PubMed ID: 21224457 [TBL] [Abstract][Full Text] [Related]
6. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine. Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400 [TBL] [Abstract][Full Text] [Related]
7. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status. Marin M; Yawn BP; Hales CM; Wollan PC; Bialek SR; Zhang J; Kurland MJ; Harpaz R Hum Vaccin Immunother; 2015; 11(5):1157-64. PubMed ID: 25806911 [TBL] [Abstract][Full Text] [Related]
8. Vaccination: a new option to reduce the burden of herpes zoster. Mick G Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Pellissier JM; Brisson M; Levin MJ Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938 [TBL] [Abstract][Full Text] [Related]
10. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. Zhang J; Xie F; Delzell E; Chen L; Winthrop KL; Lewis JD; Saag KG; Baddley JW; Curtis JR JAMA; 2012 Jul; 308(1):43-9. PubMed ID: 22760290 [TBL] [Abstract][Full Text] [Related]
12. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. Langan SM; Smeeth L; Margolis DJ; Thomas SL PLoS Med; 2013; 10(4):e1001420. PubMed ID: 23585738 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360 [TBL] [Abstract][Full Text] [Related]
14. Trends and disparity in zoster vaccine uptake in a managed care population. Hechter RC; Tartof SY; Jacobsen SJ; Smith N; Tseng HF Vaccine; 2013 Sep; 31(41):4564-8. PubMed ID: 23928461 [TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Mills R; Tyring SK; Levin MJ; Parrino J; Li X; Coll KE; Stek JE; Schlienger K; Chan IS; Silber JL Vaccine; 2010 Jun; 28(25):4204-9. PubMed ID: 20416263 [TBL] [Abstract][Full Text] [Related]
16. Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years. Tseng HF; Harpaz R; Luo Y; Hales CM; Sy LS; Tartof SY; Bialek S; Hechter RC; Jacobsen SJ J Infect Dis; 2016 Jun; 213(12):1872-5. PubMed ID: 26908728 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. Bilcke J; Marais C; Ogunjimi B; Willem L; Hens N; Beutels P Vaccine; 2012 Jan; 30(3):675-84. PubMed ID: 22120193 [TBL] [Abstract][Full Text] [Related]
18. Risk of herpes zoster following mRNA COVID-19 vaccine administration. Florea A; Wu J; Qian L; Lewin B; Sy LS; Lin IC; Ku JH; Tseng HF Expert Rev Vaccines; 2023; 22(1):643-649. PubMed ID: 37416973 [TBL] [Abstract][Full Text] [Related]
19. The epidemiology of herpes zoster in patients with newly diagnosed cancer. Habel LA; Ray GT; Silverberg MJ; Horberg MA; Yawn BP; Castillo AL; Quesenberry CP; Li Y; Sadier P; Tran TN Cancer Epidemiol Biomarkers Prev; 2013 Jan; 22(1):82-90. PubMed ID: 23118142 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: A retrospective cohort study. Sun Y; Jackson K; Dalmon CA; Shapiro BL; Nie S; Wong C; Arnold BF; Porco TC; Acharya NR Vaccine; 2021 Jun; 39(29):3974-3982. PubMed ID: 34116874 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]